Master protocols to study multiple therapies, multiple diseases, or both

New England Journal of Medicine

Volumn 377, Issue 1, 2017, Pages 62-70

  Woodcock, Janet ^a   LaVange, Lisa M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; BIOLOGICAL MARKER; CETUXIMAB; ERLOTINIB; IMATINIB; PATRITUMAB; SORAFENIB; VANDETANIB; VEMURAFENIB;

ADVANCED CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL PROTOCOL; COLORECTAL CANCER; DRUG TARGETING; EVENT FREE SURVIVAL; HEALTH CARE PLANNING; HEMATOLOGIC DISEASE; HUMAN; MULTICENTER STUDY (TOPIC); NEOADJUVANT THERAPY; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID MALIGNANT NEOPLASM; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); DISEASES; METHODOLOGY; ORGANIZATION AND MANAGEMENT; THERAPY;

CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DISEASE; HUMANS; RESEARCH DESIGN; THERAPEUTICS;

EID: 85021823745     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1510062     Document Type: Review

References (38)

1. Clinical trial designs for studying targeted therapies. ASCO Daily News. May 31, 2015 (https://am.asco.org/ clinical-trial-designs-studying-targeted-therapies).
2. Berry DA. The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 2015;9:951-9.
3. Catenacci DVT. Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 2015;9:967-96.
4. Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 2015;33:975-7.
5. Fridlyand J, Simon RM, Walrath JC, et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov 2013;12:743-55.
6. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14: 2717-25.
7. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726-36.
8. NCI-MATCH Trial (Molecular Analysis for Therapy Choice). Bethesda, MD: National Cancer Institute (http://www.cancer.gov/about-cancer/treatment/ clinical-trials/nci-supported/nci-match).
9. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1: 44-53.
10. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
11. Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011;306:2608-9.
12. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015;313:1619-20.
13. Herbst R, Rubin E, LaVange L, et al. Design of a disease-specific master protocol. Presented at the Friends of Cancer Research/Brookings Conference on Clinical Cancer Research, Washington, DC, November 14, 2012.
14. Herbst RS, Gandara DR, Hirsch FR, et al. Lung Master Protocol (Lung-MAP) — a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 2015;21:1514-24.
15. Steuer CE, Papadimitrakopoulou V, Herbst RS, et al. Innovative clinical trials: the LUNG-MAP study. Clin Pharmacol Ther 2015;97:488-91.
16. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384:164-72.
17. Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med 2016;375:11-22.
18. Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N Engl J Med 2016;375:23-34.
19. Duke Margolis Center for Health Policy. Pioneering statistical approaches to accelerate drug development through adaptive trial designs. June 30, 2016 (https://healthpolicy.duke.edu/publications/ pioneering-statistical-approaches -accelerate-drug-development-through -adaptive-trial).
20. Mullard A. Multicompany trials adapt to disciplines beyond cancer. Nat Med 2014;20:3.
21. Studies in progress. Antibacterial Leadership Resistance Group (http://arlg.org/studies-in-progress).
22. Antibiotic platform design. Austin, TX: Berry Consultants (http://www.berryconsultants.com/antibiotic-platform-design/).
23. Dodd LE, Proschan MA, Neuhaus J, et al. Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis 2016;213:1906-13.
24. The PREVAIL II Writing Group. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016; 375:1448-56.
25. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367:795-804.
26. Dominantly Inherited Alzheimer Network Trial: an opportunity to prevent dementia (DIAN TU). Bethesda, MD: National Institute on Aging (https://www .nia.nih.gov/alzheimers/clinical-trials/ dominantly-inherited-alzheimer-net work-trial-opportunit y-prevent-dementia).
27. Drazen JM, Lenfant C, Hurd SS. Acorns and inhalers: the Asthma Clinical Research Network. J Allergy Clin Immu-nol 2007;119:28-9.
28. Davis SM, Koch GG, Davis CE, LaVange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophr Bull 2003;29:73-80.
29. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
30. LaVange LM, Sridhara R. Statistical considerations in designing master protocols. Presented at the Innovations in Breast Cancer Drug Development — Next Generation Oncology Trials, Breast Cancer Workshop, Bethesda, MD, October 21, 2014 (http://wayback.archive-it.org/7993/20161023010547/http://www.fda.gov/ downloads/Drugs/NewsEvents/ UCM423368.pdf).
31. Sridhara R, He K, Nie L, Shen Y-L, Tang S. Current statistical challenges in oncology clinical trials in the era of targeted therapy. Stat Biopharm Res 2015;7: 348-56.
32. Saville BR, Connor JT, Ayers GD, Alvarez J. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials 2014;11:485-93.
33. Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials 2013;10:720-34.
34. Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials 2016;13:358-66.
35. Hong F, Simon R. Run-in phase III trial design with pharmacodynamics predictive biomarkers. J Natl Cancer Inst 2013;105:1628-33.
36. Hey SP, Kimmelman J. Are outcome-adaptive allocation trials ethical? Clin Trials 2015;12:102-6.
37. Berry D, Esserman L. Adaptive randomization of neratinib in early breast cancer N Engl J Med 2016;375:1592-3.
38. Hunter DJ, D’Agostino RB Sr. Let’s not put all our eggs in one basket. N Engl J Med 2015;373:691-3.